Contributions
Abstract: EP1532
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background and purpose: Increased signal-to-noise ratio has improved the image quality of 3 Tesla (T) MRI in comparison to 1.5T. This allows an improved detection of multiple sclerosis (MS) lesions. However, to date it remains unclear if this is clinically relevant in the diagnosis and follow-up of clinically isolated syndrome (CIS) suggestive of MS. The purpose of this multi-centre study was to investigate whether 3T MRI affects lesion detection and diagnosis in CIS.
Materials and methods: We recruited 66 CIS patients and 26 healthy controls in 6 European MS centres. All subjects received baseline 1.5T and 3T brain and spinal cord MRI. Patients who had not converted to MS during follow-up also received brain MRIs at 3-6 months and at 12-15 months. The number of lesions per anatomical region was scored separately on 1.5T and 3T images by three raters in consensus and subsequently dissemination in space and time (DIS and DIT) were determined according to the 2010 revision of the McDonald criteria. Statistical analysis was performed using the Wilcoxon signed-rank test for continuous variables and the McNemar test for dichotomous outcomes in SPSS 22.0.
Results: Interim analysis of 32 patients (age 34.8±9.0 years) and 12 controls (age 36.2±8.1 years) showed a trend towards a difference in the total number of lesions per patient, with a mean number of lesions per patient of 12.8 on 1.5T and 14.4 on 3T (p=0.088). This was mainly due to a significant difference in detection of periventricular lesions at baseline, with a mean per patient of 3.5 on 1.5T and 4.5 on 3T (p=0.018). For healthy controls no significant difference was seen between the two field strengths. DIS and DIT, and with that the diagnoses of MS, were similar between 3T and 1.5T
(DIS p=1.00, DIT p=0.625, MS p=0.375). Full analysis will be presented.
Conclusion: We have extended previous findings obtained in single-centre studies by showing that 3T increases lesion detection in CIS suggestive of MS, but does not significantly influence the fulfilment of the criteria for DIS and DIT.
Disclosure:
M.H., J.B., I.K., M.V., N.C., E.S., M.Am., J.L. and B.W. have nothing to disclose.
M.An. received travel and conference fees support from Novartis and Biogen.
P.P. has received funding for travel from Novartis, Genzyme and Bracco and speaker honoraria from Biogen.
J.K. has accepted speaker and consultancy fees from Merck-Serono, Teva, Biogen, Genzyme, Roche and Novartis.
C.O-G. received honoraria as speaker from Biogen-Idec, Bayer-Schering, Merck-Serono, Teva, Genzyme and Novartis.
O.C. serves as a consultant for Biogen, Roche, Teva, Genzyme, Novartis and GE Healthcare.
C.G. received fees as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis and Merck-Serono, and received a grant for research by Teva.
C.L. holds an endowed professorship supported by the Novartis foundation, has received consulting and speaker's honoraria from Biogen-Idec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Merck-Serono and Novartis.
M.W. serves as a consultant for Roche, Novartis and Biogen.
F.B. serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, Roche, Synthon BV and Jansen Research.
Abstract: EP1532
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background and purpose: Increased signal-to-noise ratio has improved the image quality of 3 Tesla (T) MRI in comparison to 1.5T. This allows an improved detection of multiple sclerosis (MS) lesions. However, to date it remains unclear if this is clinically relevant in the diagnosis and follow-up of clinically isolated syndrome (CIS) suggestive of MS. The purpose of this multi-centre study was to investigate whether 3T MRI affects lesion detection and diagnosis in CIS.
Materials and methods: We recruited 66 CIS patients and 26 healthy controls in 6 European MS centres. All subjects received baseline 1.5T and 3T brain and spinal cord MRI. Patients who had not converted to MS during follow-up also received brain MRIs at 3-6 months and at 12-15 months. The number of lesions per anatomical region was scored separately on 1.5T and 3T images by three raters in consensus and subsequently dissemination in space and time (DIS and DIT) were determined according to the 2010 revision of the McDonald criteria. Statistical analysis was performed using the Wilcoxon signed-rank test for continuous variables and the McNemar test for dichotomous outcomes in SPSS 22.0.
Results: Interim analysis of 32 patients (age 34.8±9.0 years) and 12 controls (age 36.2±8.1 years) showed a trend towards a difference in the total number of lesions per patient, with a mean number of lesions per patient of 12.8 on 1.5T and 14.4 on 3T (p=0.088). This was mainly due to a significant difference in detection of periventricular lesions at baseline, with a mean per patient of 3.5 on 1.5T and 4.5 on 3T (p=0.018). For healthy controls no significant difference was seen between the two field strengths. DIS and DIT, and with that the diagnoses of MS, were similar between 3T and 1.5T
(DIS p=1.00, DIT p=0.625, MS p=0.375). Full analysis will be presented.
Conclusion: We have extended previous findings obtained in single-centre studies by showing that 3T increases lesion detection in CIS suggestive of MS, but does not significantly influence the fulfilment of the criteria for DIS and DIT.
Disclosure:
M.H., J.B., I.K., M.V., N.C., E.S., M.Am., J.L. and B.W. have nothing to disclose.
M.An. received travel and conference fees support from Novartis and Biogen.
P.P. has received funding for travel from Novartis, Genzyme and Bracco and speaker honoraria from Biogen.
J.K. has accepted speaker and consultancy fees from Merck-Serono, Teva, Biogen, Genzyme, Roche and Novartis.
C.O-G. received honoraria as speaker from Biogen-Idec, Bayer-Schering, Merck-Serono, Teva, Genzyme and Novartis.
O.C. serves as a consultant for Biogen, Roche, Teva, Genzyme, Novartis and GE Healthcare.
C.G. received fees as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis and Merck-Serono, and received a grant for research by Teva.
C.L. holds an endowed professorship supported by the Novartis foundation, has received consulting and speaker's honoraria from Biogen-Idec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Merck-Serono and Novartis.
M.W. serves as a consultant for Roche, Novartis and Biogen.
F.B. serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, Roche, Synthon BV and Jansen Research.